Stock Track | Repligen Soars 5.74% Intraday on Strong Q1 Results, Beats Estimates and Raises Guidance

Stock Track
05/05

Repligen Corporation's stock surged 5.74% during intraday trading on Tuesday, following the release of its first quarter 2026 financial results.

The bioprocessing technology company reported Q1 revenue of $194 million, a 15% year-over-year increase that slightly exceeded analyst expectations. More notably, adjusted earnings per share rose 23% to $0.48, significantly beating the consensus estimate of $0.39. The strong performance was driven by 11% organic revenue growth and 160 basis points of adjusted operating margin expansion.

Management reinforced investor confidence by reiterating full-year organic revenue growth guidance of 9%-13% while raising adjusted EPS guidance to $1.97-$2.05. The company also highlighted strategic progress including the divestiture of its non-core Polymem filtration business and a new OEM partnership in China designed to increase competitiveness and access to local manufacturing.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10